[{"edinetCode":"E00922","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6492.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":285917000.0,"sharesOwendPercent":0.7186,"outstandingShares":null,"numberOfSubsidiary":16.0,"bps":1159.47,"equityRatio":0.58,"cashAndCashEquivalents":105603000000.0,"assets":793950000000.0,"currentAssets":376454000000.0,"fixedAsset":417495000000.0,"tangibleFixedAssets":59253000000.0,"intangibleFixedAssets":304310000000.0,"investmentAndOtherAssets":53931000000.0,"liabilities":333293000000.0,"currentLiabilities":228447000000.0,"shorTermDept":40000000000.0,"currentPortionOfBonds":10000000000.0,"currentPortionOfLongTermDebt":8000000000.0,"fixedLiabilities":104846000000.0,"bonds":10000000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":460656000000.0,"capitalStock":401221000000.0,"capital":22400000000.0,"capitalSurplus":15860000000.0,"accumulatedEarnings":363627000000.0,"treasuryStock":-666000000.0,"valuationAndConversionAdjustments":59435000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":411638000000.0,"costOfSales":100078000000.0,"grossProfit":311560000000.0,"sgaExpenses":258808000000.0,"salaryAndBenefit":null,"depreciationAndSGA":5654000000.0,"RDExpenses":80819000000.0,"operatingIncome":52759000000.0,"nonOperatingIncome":3519000000.0,"nonOperatingExpenses":1937000000.0,"interestExpense":631000000.0,"ordinaryProfit":54341000000.0,"extraordinaryGain":5754000000.0,"extraordinaryLoss":12878000000.0,"incomeBeforeTax":47217000000.0,"incomeTaxes":18226000000.0,"netIncome":28991000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":28991000000.0,"comprehensiveIncome":21145000000.0,"eps":72.97,"dilutedEps":null,"dividendPerShare":null,"per":25.2,"roe":0.064,"cashFlowFromOperatingActivities":21624000000.0,"depreciationAndCashflowFromOperatingActivities":13058000000.0,"cashFlowFromInvestingActivities":-59729000000.0,"cashFlowFromFinancialActivities":9881000000.0,"changesInCashAndCashEquivalents":-29971000000.0,"列1":"asr","submitDate":"2017\/6\/22","stockCode":4506,"accountingYear":"第197期(自　平成28年４月１日　至　平成29年３月31日)","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6268.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":293047000.0,"sharesOwendPercent":0.7378,"outstandingShares":null,"numberOfSubsidiary":null,"bps":1215.84,"equityRatio":0.603,"cashAndCashEquivalents":147775000000.0,"assets":null,"currentAssets":null,"fixedAsset":null,"tangibleFixedAssets":null,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":null,"currentLiabilities":null,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":null,"capitalSurplus":null,"accumulatedEarnings":null,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":30609000000.0,"eps":94.45,"dilutedEps":null,"dividendPerShare":null,"per":18.9,"roe":0.08,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2018\/6\/19","stockCode":4506,"accountingYear":"第198期(自　2017年４月１日　至　2018年３月31日)","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6140.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":298294000.0,"sharesOwendPercent":0.7508,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":834717000000.0,"currentAssets":373268000000.0,"fixedAsset":null,"tangibleFixedAssets":59485000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":336579000000.0,"currentLiabilities":198174000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":15861000000.0,"accumulatedEarnings":431799000000.0,"treasuryStock":-674000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":113553000000.0,"grossProfit":null,"sgaExpenses":180439000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":22.4,"roe":null,"cashFlowFromOperatingActivities":48711000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-35049000000.0,"cashFlowFromFinancialActivities":-28645000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2019\/6\/20","stockCode":4506,"accountingYear":"第199期(自　2018年４月１日　至　2019年３月31日)","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":808062000000.0,"currentAssets":366058000000.0,"fixedAsset":null,"tangibleFixedAssets":70059000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":318628000000.0,"currentLiabilities":193227000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":15861000000.0,"accumulatedEarnings":431048000000.0,"treasuryStock":-675000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":28953000000.0,"grossProfit":null,"sgaExpenses":27887000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":8247000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":16675000000.0,"cashFlowFromFinancialActivities":-9320000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/5","stockCode":4506,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":296702000.0,"sharesOwendPercent":0.7468,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":805037000000.0,"currentAssets":382680000000.0,"fixedAsset":null,"tangibleFixedAssets":69026000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":293372000000.0,"currentLiabilities":193216000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":15861000000.0,"accumulatedEarnings":451606000000.0,"treasuryStock":-676000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":56286000000.0,"grossProfit":null,"sgaExpenses":47030000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":31777000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":10808000000.0,"cashFlowFromFinancialActivities":-11175000000.0,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2019\/11\/1","stockCode":4506,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1115150000000.0,"currentAssets":348206000000.0,"fixedAsset":null,"tangibleFixedAssets":71087000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":592800000000.0,"currentLiabilities":489087000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":15861000000.0,"accumulatedEarnings":460277000000.0,"treasuryStock":-676000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":93342000000.0,"grossProfit":null,"sgaExpenses":97800000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":36773000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-284712000000.0,"cashFlowFromFinancialActivities":240475000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/5","stockCode":4506,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6457.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":297341000.0,"sharesOwendPercent":0.7484,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1252880000000.0,"currentAssets":364090000000.0,"fixedAsset":null,"tangibleFixedAssets":65748000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":620773000000.0,"currentLiabilities":496498000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":14655000000.0,"accumulatedEarnings":457330000000.0,"treasuryStock":-677000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":129673000000.0,"grossProfit":null,"sgaExpenses":154348000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":13.7,"roe":null,"cashFlowFromOperatingActivities":46128000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":-312684000000.0,"cashFlowFromFinancialActivities":231081000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2020\/6\/23","stockCode":4506,"accountingYear":"第200期(自　2019年４月１日　至　2020年３月31日)","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1236190000000.0,"currentAssets":353479000000.0,"fixedAsset":null,"tangibleFixedAssets":64518000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":599394000000.0,"currentLiabilities":476986000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":17546000000.0,"accumulatedEarnings":470027000000.0,"treasuryStock":-677000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":35970000000.0,"grossProfit":null,"sgaExpenses":49012000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":517000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":21533000000.0,"cashFlowFromFinancialActivities":-9334000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/7","stockCode":4506,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":298146000.0,"sharesOwendPercent":0.7504,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1238490000000.0,"currentAssets":377422000000.0,"fixedAsset":null,"tangibleFixedAssets":63733000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":602491000000.0,"currentLiabilities":365477000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":16641000000.0,"accumulatedEarnings":488845000000.0,"treasuryStock":-677000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":70694000000.0,"grossProfit":null,"sgaExpenses":94173000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":26069000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":19372000000.0,"cashFlowFromFinancialActivities":-9793000000.0,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2020\/11\/5","stockCode":4506,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1308840000000.0,"currentAssets":464715000000.0,"fixedAsset":null,"tangibleFixedAssets":62756000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":670267000000.0,"currentLiabilities":263168000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":16432000000.0,"accumulatedEarnings":516243000000.0,"treasuryStock":-678000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":104795000000.0,"grossProfit":null,"sgaExpenses":147019000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":107880000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":35562000000.0,"cashFlowFromFinancialActivities":-18414000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/4","stockCode":4506,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":6822.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":297059000.0,"sharesOwendPercent":0.7476,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1308130000000.0,"currentAssets":459795000000.0,"fixedAsset":null,"tangibleFixedAssets":64966000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":659949000000.0,"currentLiabilities":278147000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":15855000000.0,"accumulatedEarnings":508677000000.0,"treasuryStock":-679000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":137773000000.0,"grossProfit":null,"sgaExpenses":190373000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":13.6,"roe":null,"cashFlowFromOperatingActivities":135601000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":8875000000.0,"cashFlowFromFinancialActivities":-57215000000.0,"changesInCashAndCashEquivalents":null,"列1":"asr","submitDate":"2021\/6\/24","stockCode":4506,"accountingYear":"第201期(自　2020年４月１日　至　2021年３月31日)","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1276710000000.0,"currentAssets":442640000000.0,"fixedAsset":null,"tangibleFixedAssets":64072000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":638014000000.0,"currentLiabilities":256813000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":17558000000.0,"accumulatedEarnings":509975000000.0,"treasuryStock":-679000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":38476000000.0,"grossProfit":null,"sgaExpenses":62061000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-32805000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":17688000000.0,"cashFlowFromFinancialActivities":-6904000000.0,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/5","stockCode":4506,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":302876000.0,"sharesOwendPercent":0.7624,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1267430000000.0,"currentAssets":449053000000.0,"fixedAsset":null,"tangibleFixedAssets":63662000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":618749000000.0,"currentLiabilities":260897000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":15385000000.0,"accumulatedEarnings":542041000000.0,"treasuryStock":-680000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":76854000000.0,"grossProfit":null,"sgaExpenses":124673000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-28208000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":3632000000.0,"cashFlowFromFinancialActivities":-13246000000.0,"changesInCashAndCashEquivalents":null,"列1":"q2r","submitDate":"2021\/11\/4","stockCode":4506,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0},{"edinetCode":"E00922","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":null,"cashAndCashEquivalents":null,"assets":1295910000000.0,"currentAssets":467297000000.0,"fixedAsset":null,"tangibleFixedAssets":64034000000.0,"intangibleFixedAssets":null,"investmentAndOtherAssets":null,"liabilities":630142000000.0,"currentLiabilities":271692000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":null,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":null,"capitalStock":null,"capital":22400000000.0,"capitalSurplus":15688000000.0,"accumulatedEarnings":547668000000.0,"treasuryStock":-680000000.0,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":117835000000.0,"grossProfit":null,"sgaExpenses":189029000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":null,"nonOperatingIncome":null,"nonOperatingExpenses":null,"interestExpense":null,"ordinaryProfit":null,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":null,"incomeTaxes":null,"netIncome":null,"netIncomeAttributableToOwnersOfTheParentCompany":null,"comprehensiveIncome":null,"eps":null,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":9061000000.0,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":7259000000.0,"cashFlowFromFinancialActivities":-20395000000.0,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/3","stockCode":4506,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"IFRS","consolidatedAccounting":true,"edinetCode2":"E00922","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":22400,"settlementDate":"2022\/3\/31","submitterName":"大日本住友製薬株式会社","submitterNameEnglish":"Sumitomo Dainippon Pharma Co.,Ltd.","submitterNameKana":"ダイニッポンスミトモセイヤクカブシキガイシャ","location":"大阪市中央区道修町２丁目６番８号","industory":"医薬品","corporateNumber":3120000000000.0}]